Loading organizations...
Archipel Capital operates as a venture capital firm, focusing its investment strategy on providing growth capital. Employing a co-investment model, it partners with other venture capital entities to support its portfolio. Primary sector interests include biotechnology and renewable specialty industries, reflecting an intent to engage with innovative, high-potential markets.
Founded in 2005 by Gregory Gray, Archipel Capital initially aimed to capitalize on opportunities within emerging technological domains. However, the firm's early trajectory was significantly overshadowed by subsequent legal challenges involving its principal leadership, raising questions about operational integrity.
The firm's investment thesis revolved around supporting later-stage companies requiring capital for expansion. It sought to serve its limited partners and portfolio companies by facilitating development. Archipel Capital’s envisioned role was to drive innovation and create value within chosen industries through strategic funding and collaborative efforts.
Archipel Capital has 2 tracked investments across 1 company. The latest tracked deal is $16.2M Debt / Series C in Lineagen in February 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 18, 2015 | Lineagen | $16.2M Debt / Series C | David Kabakoff | Kickstart Ventures, Mesa Verde Venture Partners, Mountain Group Partners, David Fitzgerald, Prairiegold Venture Partners, Sanderling Ventures, Signal Peak Ventures, Silicon Valley Bank, University Venture Fund |
| Dec 18, 2013 | Lineagen | $3.5M Other Equity / Series C | Sanderling Ventures, Signal Peak Ventures | Hatteras Funds, Kickstart Seed Fund, Mesa Verde Venture Partners, Prairiegold Venture Partners, University Venture Fund |
